Skip to main content

Advertisement

SpringerLink
Log in

Fibrate Therapy in the Management of Diabetic Dyslipidemia: There is No ACCORD to be Found

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Mixed dyslipidemia is a complex clinical entity that contributes significantly to the increased risk for cardiovascular morbidity and mortality that is observed in patients with type 2 diabetes mellitus. Insulin resistance is associated with reduced serum lipoprotein lipase activity, increased serum levels of very low-density lipoproteins and triglyceride, low serum high-density lipoproteins, and increased concentrations of small, dense low-density lipoproteins. Combinations of medications are frequently required in order to achieve guideline-specified goals for the various lipid fractions of diabetic patients. The fibric acid derivatives (fibrates) are effective agents for raising serum levels of high-density lipoproteins and decreasing levels of triglycerides. A number of trials have demonstrated that among patients with high triglycerides and low HDL, fibrates do beneficially impact cardiovascular morbidity in diabetic and nondiabetic individuals. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial suggests that the addition of fenofibrate to ongoing statin therapy in patients with type 2 diabetes mellitus offers limited benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

  2. Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46:1855–1862.

    Article  CAS  PubMed  Google Scholar 

  3. Toth PP, Cadman C: Implications of recent statin trials for primary care practice. J Clin Lipidol 2007, 1:182–190.

    Article  Google Scholar 

  4. Sharrett AR, Ballantyne CM, Coady SA, et al.: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104:1108–1113.

    Article  CAS  PubMed  Google Scholar 

  5. Jonsdottir LS, Sigfusson N, Gudnason V, et al.: Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk 2002, 9:67–76.

    Article  PubMed  Google Scholar 

  6. •• Sarwar N, Danesh J, Eiriksdottir G, et al.: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450–458. This is the largest meta-analysis to date demonstrating an independent relationship between serum levels of TG and risk for CHD.

    Article  CAS  PubMed  Google Scholar 

  7. • Bansal S, Buring JE, Rifai N, et al.: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309–316. This observational study establishes the potential importance of evaluating nonfasting serum TG when estimating risk for CHD in women.

    Article  CAS  PubMed  Google Scholar 

  8. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299–308.

    Article  CAS  PubMed  Google Scholar 

  9. Castelli WP: Cholesterol and lipids in the risk of coronary artery disease—the Framingham Heart Study. Can J Cardiol 1988, 4(Suppl A):5A–10A.

    Google Scholar 

  10. Assmann G, Cullen P, Schulte H: The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998, 19(Suppl A):A2–A11.

    Google Scholar 

  11. Toth PP: High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects. Dis Mon 2001, 47:369–416.

    Article  CAS  PubMed  Google Scholar 

  12. Standards of medical care in diabetes. Diabetes Care 2005, 28(Suppl 1):S4–S36.

  13. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685–696.

    Article  CAS  PubMed  Google Scholar 

  14. Kearney PM, Blackwell L, Collins R, et al.: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117–125.

    Article  CAS  PubMed  Google Scholar 

  15. Staels B, Fruchart JC: Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54:2460–2470.

    Article  CAS  PubMed  Google Scholar 

  16. Auwerx J, Schoonjans K, Fruchart JC, Staels B: Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 1996, 124(Suppl):S29–37.

    Article  CAS  PubMed  Google Scholar 

  17. Zhu D, Ganji SH, Kamanna VS, Kashyap ML: Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells. Atherosclerosis 2002, 164:221–228.

    Article  CAS  PubMed  Google Scholar 

  18. Chinetti-Gbaguidi G, Rigamonti E, Helin L, et al.: Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. J Lipid Res 2005, 46:2717–2725.

    Article  CAS  PubMed  Google Scholar 

  19. Fruchart JC, Staels B, Duriez P: The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 2001, 3:83–92.

    Article  CAS  PubMed  Google Scholar 

  20. Delerive P, De Bosscher K, Besnard S, et al.: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274:32048–32054.

    Article  CAS  PubMed  Google Scholar 

  21. Huttunen JK, Frick MH, Heinonen OP, et al.: Helsinki Heart Study. New perspectives in the prevention of coronary heart disease. Drugs 1988, 36(Suppl 3):32–36.

    Article  PubMed  Google Scholar 

  22. Robins SJ: Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol 2001, 88:19N–23N.

    Article  CAS  PubMed  Google Scholar 

  23. Bloomfield Rubins H, Davenport J, Babikian V, et al.: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001, 103:2828–2833.

    Google Scholar 

  24. Rubins HB, Robins SJ, Collins D, et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597–2604.

    Article  CAS  PubMed  Google Scholar 

  25. Robins SJ, Rubins HB, Faas FH, et al.: Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 2003, 26:1513–1517.

    Article  CAS  PubMed  Google Scholar 

  26. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21–27.

  27. Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849–1861.

    Article  CAS  PubMed  Google Scholar 

  28. •• Scott R, O’Brien R, Fulcher G, et al.: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493–498. This is a post hoc analysis of the FIELD trial demonstrating once again that fibrate therapy reduces risk for cardiovascular events in patients with hypertriglyceridemia and low HDL-C.

    Article  CAS  PubMed  Google Scholar 

  29. Frick MH, Syvanne M, Nieminen MS, et al.: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997, 96:2137–2143.

    CAS  PubMed  Google Scholar 

  30. de Faire U, Ericsson CG, Grip L, et al.: Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 1996, 17(Suppl F):37–42.

    Google Scholar 

  31. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905–910.

  32. Ginsberg HN, Elam MB, Lovato LC, et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563–1574.

    Article  PubMed  Google Scholar 

  33. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J: High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005, 21:1927–1934.

    Article  CAS  PubMed  Google Scholar 

  34. Jacobs MJ, Kleisli T, Pio JR, et al.: Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005, 70:263–269.

    Article  PubMed  Google Scholar 

Download references

Disclosure

Dr. Toth has worked as a consultant for Abbott, AstraZeneca, Kowa, and Merck and Co. He is a member of the Speakers’ Bureau for Abbott, AstraZeneca, GlaxoSmithKline, Merck and Co., Pfizer, and Takeda.

Author information

Authors and Affiliations

  1. Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL, 61081, USA

    Peter P. Toth

  2. University of Illinois School of Medicine, Peoria, IL, USA

    Peter P. Toth

Authors
  1. Peter P. Toth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter P. Toth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toth, P.P. Fibrate Therapy in the Management of Diabetic Dyslipidemia: There is No ACCORD to be Found. Curr Atheroscler Rep 12, 331–335 (2010). https://doi.org/10.1007/s11883-010-0126-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-010-0126-3

Keywords

Search

Navigation